The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | MGTA-145 and plerixafor for HSC mobilization in myeloma
Surbhi Sidana, MD, Stanford University, Stanford, CA, shares an update on a Phase II study (NCT04552743) of MGTA-145, a CXCR2 agonist, plus plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous stem cell transplant (auto-SCT) in patients with multiple myeloma. The primary endpoint of the study is collection of 2×10^6 CD34+ cells/kg within two days of mobilization/apheresis. Dr Sidana discusses the findings of interim analysis of data on mobilization from fifteen patients. 100% of patients met the primary endpoint. The secondary endpoint of 4 and 6×10^6 CD34+ cells/kg in two or less days was met by 90% and 80% of patients respectively. Overall, MGTA-145 was found to be well-tolerated. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
